Craig Hallum Forecasts NeurAxis’ Q3 Earnings (NASDAQ:NRXS)

NeurAxis, Inc. (NASDAQ:NRXS) – Research analysts at Craig Hallum issued their Q3 2026 EPS estimates for NeurAxis in a report released on Tuesday, September 29th. Craig Hallum analyst C. Knickerbocker expects that the company will post earnings of ($0.21) per share for the quarter. Craig Hallum also issued estimates for NeurAxis’ Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($0.76) EPS and FY2027 earnings at ($0.27) EPS.

Separately, Zacks Research upgraded shares of NeurAxis to a “hold” rating in a research note on Friday, October 2nd. One research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $13.00.

NeurAxis Stock Down 5.2%

NeurAxis stock opened at $6.78 on Monday. NeurAxis has a twelve month low of $2.21 and a twelve month high of $9.33. The firm has a 50 day moving average price of $6.54 and a 200-day moving average price of $7.00. The company has a market capitalization of $85.14 million, a P/E ratio of -3.68 and a beta of 1.38.

Institutional Investors Weigh In On NeurAxis

Large investors have recently added to or reduced their stakes in the company. Panoramic Capital LLC bought a new position in NeurAxis during the second quarter worth about $841,000. Elevation Point Wealth Partners LLC bought a new stake in shares of NeurAxis in the second quarter valued at approximately $105,000. BlackRock Inc. bought a new stake in shares of NeurAxis in the second quarter valued at approximately $429,000. AIGH Capital Management LLC purchased a new stake in shares of NeurAxis during the 2nd quarter valued at approximately $3,801,000. Finally, Corsair Capital Management L.P. purchased a new stake in shares of NeurAxis during the 1st quarter valued at approximately $74,000. Hedge funds and other institutional investors own 11.77% of the company’s stock.

About NeurAxis

NeurAxis, Inc is a medical technology company focused on developing and commercializing neuromodulation therapies for functional gastrointestinal disorders. The company’s primary product is IB-Stim, a minimally invasive device that delivers percutaneous electrical nerve field stimulation through the external ear.

IB-Stim is designed to modulate neural pathways associated with functional abdominal pain and related gastrointestinal symptoms. It has been cleared by the U.S. Food and Drug Administration for use in patients, including adolescents, with functional abdominal pain associated with irritable bowel syndrome.